Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$0.29 - $0.64 $760 - $1,678
-2,623 Reduced 0.91%
286,544 $87,000
Q4 2022

Feb 14, 2023

BUY
$0.38 - $22.5 $3,483 - $206,235
9,166 Added 3.27%
289,167 $113,000
Q3 2022

Nov 10, 2022

BUY
$0.73 - $23.4 $10,306 - $330,361
14,118 Added 5.31%
280,001 $198,000
Q2 2022

Aug 11, 2022

BUY
$0.66 - $1.81 $50,511 - $138,524
76,533 Added 40.42%
265,883 $215,000
Q1 2022

May 12, 2022

SELL
$1.27 - $2.47 $1,502 - $2,922
-1,183 Reduced 0.62%
189,350 $314,000
Q4 2021

Feb 10, 2022

SELL
$2.21 - $3.22 $7,639 - $11,131
-3,457 Reduced 1.78%
190,533 $446,000
Q3 2021

Nov 12, 2021

BUY
$2.8 - $3.72 $11,424 - $15,177
4,080 Added 2.15%
193,990 $603,000
Q2 2021

Aug 05, 2021

SELL
$2.61 - $4.17 $44,884 - $71,711
-17,197 Reduced 8.3%
189,910 $636,000
Q1 2021

May 06, 2021

SELL
$2.91 - $4.32 $21,577 - $32,032
-7,415 Reduced 3.46%
207,107 $644,000
Q4 2020

Feb 10, 2021

BUY
$2.15 - $3.5 $40,235 - $65,499
18,714 Added 9.56%
214,522 $590,000
Q3 2020

Nov 12, 2020

SELL
$2.77 - $6.17 $48,868 - $108,851
-17,642 Reduced 8.27%
195,808 $560,000
Q2 2020

Aug 13, 2020

BUY
$0.87 - $3.13 $95,769 - $344,550
110,080 Added 106.49%
213,450 $662,000
Q1 2020

May 06, 2020

BUY
$0.73 - $1.91 $23,648 - $61,874
32,395 Added 45.64%
103,370 $98,000
Q4 2019

Feb 05, 2020

BUY
$0.48 - $1.38 $3,517 - $10,112
7,328 Added 11.51%
70,975 $98,000
Q3 2019

Oct 23, 2019

BUY
$0.47 - $1.05 $1,370 - $3,062
2,917 Added 4.8%
63,647 $30,000
Q2 2019

Aug 14, 2019

BUY
$0.65 - $2.12 $39,474 - $128,747
60,730 New
60,730 $71,000
Q2 2018

Aug 06, 2018

SELL
$2.75 - $3.85 $74,071 - $103,699
-26,935 Closed
0 $0
Q1 2018

May 02, 2018

BUY
$3.5 - $4.47 $32,585 - $41,615
9,310 Added 52.82%
26,935 $94,000
Q3 2017

Nov 06, 2017

BUY
$3.15 - $4.01 $55,518 - $70,676
17,625
17,625 $68,000

Others Institutions Holding VBIV

About VBI Vaccines Inc


  • Ticker VBIV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 258,256,992
  • Market Cap $5.17M
  • Description
  • VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The...
More about VBIV
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.